See the DrugPatentWatch profile for Cyclophosphamide
Cyclophosphamide is an alkylating agent used in chemotherapy to treat various cancers and as an immunosuppressant for autoimmune diseases. It is a prodrug, meaning it requires activation by enzymes in the liver to become pharmacologically active [1].
How does cyclophosphamide work?
Cyclophosphamide is converted in the liver to active metabolites, primarily 4-hydroxycyclophosphamide and phosphoramide mustard [2]. Phosphoramide mustard is the cytotoxic component. It works by alkylating DNA, meaning it attaches an alkyl group to the DNA molecule. This alkylation interferes with DNA replication and transcription, ultimately leading to cell death. It also works by cross-linking DNA strands, which further prevents DNA from being processed by cellular machinery and triggers programmed cell death (apoptosis) [2].
What conditions is cyclophosphamide used to treat?
Cyclophosphamide is a broad-spectrum antineoplastic agent used in the treatment of numerous cancers. These include lymphomas (Hodgkin's and non-Hodgkin's), multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute leukemias, neuroblastoma, retinoblastoma, and ovarian cancer [1]. It is also used in breast cancer treatment, often in combination with other chemotherapy drugs [3]. Beyond cancer, cyclophosphamide is prescribed to manage severe autoimmune conditions like lupus nephritis, rheumatoid arthritis, and granulomatosis with polyangiitis, where its immunosuppressive properties are beneficial [1].
What are the potential side effects of cyclophosphamide?
Like many chemotherapy drugs, cyclophosphamide can cause a range of side effects. Common adverse effects include myelosuppression (a decrease in bone marrow activity, leading to low blood cell counts), nausea, vomiting, hair loss (alopecia), and fatigue [1]. More serious potential side effects include hemorrhagic cystitis (bleeding in the bladder), which can be mitigated with hydration and a protective agent called mesna [4]. Other risks involve increased susceptibility to infections due to immunosuppression, infertility, and a long-term risk of developing secondary cancers.
What is the typical dosage and administration of cyclophosphamide?
Dosage and administration vary significantly depending on the condition being treated, the patient's overall health, and whether it is used alone or in combination with other therapies. Cyclophosphamide can be administered orally in tablet form or intravenously [1]. The frequency and duration of treatment are determined by the prescribing physician.
Are there different formulations or brand names for cyclophosphamide?
Cyclophosphamide is available as a generic medication. Historically, it was marketed under brand names such as Cytoxan and Neosar [5].
What is the patent status of cyclophosphamide?
Cyclophosphamide is a very old drug, with its initial patent protection long expired. It was first patented in the 1950s [6]. As a result, it has been available as a generic medication for many years. This means that no company holds exclusive marketing rights based on original patents, and multiple manufacturers produce generic versions. Information on the patent landscape for older drugs like cyclophosphamide can be tracked on resources such as DrugPatentWatch.com [7].
How does cyclophosphamide compare to other chemotherapy drugs?
Cyclophosphamide is part of the nitrogen mustard class of alkylating agents. Its efficacy and side effect profile are compared with other agents within this class and across different chemotherapy drug categories. For instance, in breast cancer treatment, it is often used in regimens like CMF (cyclophosphamide, methotrexate, and fluorouracil) or AC (doxorubicin and cyclophosphamide) [3]. The choice of chemotherapy regimen depends on the specific cancer type, stage, and patient factors.
What are the risks associated with cyclophosphamide use for patients with specific conditions?
Patients with compromised kidney or liver function may require dose adjustments due to how cyclophosphamide is metabolized and excreted. The risk of hemorrhagic cystitis is higher in patients with pre-existing bladder conditions. Its immunosuppressive effects necessitate careful monitoring for infections, particularly in immunocompromised individuals [1]. Fertility preservation is a significant concern, especially for younger patients undergoing treatment [8].